Pretreated EGFRdel19/BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report

Corrado Orciuolo, MD; Federico Cappuzzo, MD; Lorenza Landi, MD; Blerina Resuli, MD; Silvia Carpano, MD; Antonello Vidiri, MD; Simonetta Buglioni, MS; Chiara Mandoj, MD; Gennaro Ciliberto, MD; Gabriele Minuti, MD

JTO Clinical and Research Reports (Aug 2023)

Pretreated EGFRdel19/BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report

Corrado Orciuolo, MD,
Federico Cappuzzo, MD,
Lorenza Landi, MD,
Blerina Resuli, MD,
Silvia Carpano, MD,
Antonello Vidiri, MD,
Simonetta Buglioni, MS,
Chiara Mandoj, MD,
Gennaro Ciliberto, MD,
Gabriele Minuti, MD

Affiliations

Corrado Orciuolo, MD: Corresponding author. Address for correspondence: Corrado Orciuolo, MD, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) National Cancer Institute Regina Elena, Rome, Regina Elena Institute, Via Elio Chianesi, 53, Roma Capitale, RM 00144, Italy.; Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy; Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy; IRCCS Regina Elena National Cancer Institute, Rome, Italy
Federico Cappuzzo, MD: Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy; Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy; IRCCS Regina Elena National Cancer Institute, Rome, Italy
Lorenza Landi, MD: Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy; Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy; IRCCS Regina Elena National Cancer Institute, Rome, Italy
Blerina Resuli, MD: Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy; Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy; IRCCS Regina Elena National Cancer Institute, Rome, Italy
Silvia Carpano, MD: Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy; Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy; IRCCS Regina Elena National Cancer Institute, Rome, Italy
Antonello Vidiri, MD: Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy; Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy; IRCCS Regina Elena National Cancer Institute, Rome, Italy
Simonetta Buglioni, MS: Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy; Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy; IRCCS Regina Elena National Cancer Institute, Rome, Italy
Chiara Mandoj, MD: Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy; Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy; IRCCS Regina Elena National Cancer Institute, Rome, Italy
Gennaro Ciliberto, MD: Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy; Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy; IRCCS Regina Elena National Cancer Institute, Rome, Italy
Gabriele Minuti, MD: Division of Medical Oncology 2, IRCCS National Cancer Institute Regina Elena, Rome, Italy; Clinical Trials Center: Phase 1 and Precision Medicine, IRCCS National Cancer Institute Regina Elena, Rome, Italy; IRCCS Regina Elena National Cancer Institute, Rome, Italy

Journal volume & issue: Vol. 4, no. 8
p. 100545

Abstract

Read online

Oncogene-addicted NSCLC inevitably becomes resistant to targeted therapy by developing acquired resistance through on- or off-target mechanisms, potentially detectable by liquid biopsy. We present the first reported case of a patient with pretreated EGFRdel19/BRAFV600E lung adenocarcinoma and symptomatic leptomeningeal metastasis obtaining durable clinical benefit on osimertinib, dabrafenib, and trametinib treatment.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords